Tissue Regenix Group, a regenerative medical devices company, has announced that its subsidiary 'CellRight Technologies', has entered into an agreement, effective immediately, allowing Arthrex to distribute its proprietary 'BioRinse' bone portfolio throughout Europe, with the initial focus on the UK.
This new agreement builds on the existing US relationship signed in March 2018 and is a direct result of the collaborative work that Arthrex and Tissue Regenix have been undertaking to evaluate additional business opportunities.
Steve Couldwell, CEO, Tissue Regenix Group plc commented: “I am delighted to announce an extension to our collaboration with Arthrex. Since signing the US distribution agreement in March we have continued to build a strong alliance, identifying areas where we can work together and leverage the expertise of both companies. This European agreement allows us to exploit not only our ability to import our BioRinse bone portfolio into the UK facility, but also Arthrex’s expansive distribution network, another significant milestone towards our vision of building a leading force in regenerative medicine.”
